Invitation to investor call related to the SESAR study results
Kurs
+5,69%
Likviditet
60,8 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-24 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-18 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | N/A | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2025-05-15 | N/A | Årsstämma |
| 2025-05-06 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-21 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-17 | - | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-21 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | Split SEDANA 1:4 |
| 2021-05-11 | - | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2021-05-10 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-25 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2020-05-19 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-05 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-29 | - | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2019-05-28 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-21 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-23 | - | X-dag ordinarie utdelning SEDANA 0.00 SEK |
| 2018-05-22 | - | Årsstämma |
| 2018-05-22 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-27 | - | Bokslutskommuniké 2017 |
| 2017-11-30 | - | Kvartalsrapport 2017-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Sedana Medical hereby invites to an investor call related to the results of the investigator initiated SESAR study today 19 March at 15:00 CET
Yesterday (18 March) the investigator initiated study ”Sevoflurane for sedation in Acute Respiratory Distress Syndrome (ARDS)”, the SESAR study, was published in The Journal of American Medicine (JAMA). Related to this, Sedena Medical invites investors and analysts to a digital presentation of the company’s assessment of the study results, and an opportunity to ask questions to the company’s CEO Johannes Doll and CMO Peter Sackey.
Date: Wednesday 19 March, 2025
Time: 15:00 CET
Link to presentation: https://www.finwire.tv/webcast/sedana-medical/investor-call/
If you wish to participate via teleconference: +46 8 5016 3827. Meeting ID: 825 3412 1573.
Welcome!
For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
ir@sedanamedical.com
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.